Positions

Overview

  • Oxalate is a common component of kidney stones. The theme of Dr. Fargue's research is in understanding the mechanisms underlying oxalate metabolism in healthy subjects and in patients with kidney stone disease. The initial focus has been on a rare hereditary form of oxalate kidney stones, called primary hyperoxaluria, both from a clinical perspective and basic science perspective. Dr. Fargue's recent research includes investigating mechanisms underlying calcium oxalate kidney stones.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Generation of a GLO-2 deficient mouse reveals its effects on liver carbonyl and glutathione levels..  Biochemistry and Biophysics Reports.  28:101138. 2021
    2021 Contribution of dietary oxalate and oxalate precursors to urinary oxalate excretion.  Nutrients.  13:1-13. 2021
    2021 Effect of alanine supplementation on oxalate synthesis 2021
    2020 End points for clinical trials in primary hyperoxaluria.  Clinical Journal of the American Society of Nephrology.  15:1056-1065. 2020
    2020 Future treatments for hyperoxaluria.  Current Opinion in Urology.  30:171-176. 2020
    2020 The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria 2020
    2019 Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity 2019
    2018 Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria.  Journal of the American Society of Nephrology.  29:1615-1623. 2018
    2016 High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1.  Scientific Reports.  6. 2016
    2016 Effects of alanine: Glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay 2016
    2016 MP67-02 THE EFFECT OF ALANINE ON CELL VIABILITY AND AGT ACTIVITY IN TRANSFORMED CHINESE HAMSTER OVARY CELLS 2016
    2016 MP67-03 MITOCHONDRIAL IMPLICATIONS OF GLYCOLATE METABOLISM IN PRIMARY HYPEROXALURIA 2016
    2016 Metabolism of 13C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase 2016
    2015 A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5′UTR causing primary hyperoxaluria type II 2015
    2015 MP34-04 INHIBITION OF GLYCOLATE OXIDASE REDUCES URINARY OXALATE EXCRETION IN A MOUSE MODEL OF PRIMARY HYPEROXALURIA TYPE 1 2015
    2015 Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening.  ASSAY and Drug Development Technologies.  13:16-24. 2015
    2015 Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine: Glyoxylate aminotransferase causing primary hyperoxaluria type I.  Human Molecular Genetics.  24:5500-5511. 2015
    2014 Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1 2014
    2014 Factors influencing clinical outcome in patients with primary hyperoxaluria type 1.  Kidney International.  86:1074-1076. 2014
    2013 Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1 2013
    2013 Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele.  Journal of Biological Chemistry.  288:2475-2484. 2013
    2012 The N-terminal extension is essential for the formation of the active dimeric structure of liver peroxisomal alanine:glyoxylate aminotransferase 2012
    2012 Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment..  Nephrology Dialysis Transplantation.  27:1729-1736. 2012
    2011 Hyperoxalurie primitive de type 1 : expérience française.  Néphrologie and Thérapeutique.  7:289-289. 2011
    2011 Primary hyperoxaluria.  Néphrologie and Thérapeutique.  7:249-259. 2011
    2011 Primary hyperoxaluria..  International Journal of Nephrology.  2011:864580. 2011
    2011 Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation.  Journal of the American Society of Nephrology.  22:579-585. 2011
    2010 Tacrolimus nephrotoxicity: Beware of the association of diarrhea, drug interaction and pharmacogenetics.  Pediatric Nephrology.  25:965-969. 2010
    2010 Genotype-phenotype correlation in primary hyperoxaluria type 1: The p.Gly170Arg AGXT mutation is associated with a better outcome.  Kidney International.  77:443-449. 2010
    2010 Bone metabolism in oxalosis: A single-center study using new imaging techniques and biomarkers.  Pediatric Nephrology.  25:1081-1089. 2010
    2010 Primary hyperoxaluria type 1: Strategy for organ transplantation.  Current Opinion in Organ Transplantation.  15:590-593. 2010
    2009 Survey of First-Year Medical Students to Assess Their Knowledge and Attitudes Toward Organ Transplantation and Donation.  Transplantation Proceedings.  41:634-638. 2009
    2009 Disease recurrence in paediatric renal transplantation.  Pediatric Nephrology.  24:2097-2108. 2009
    2009 Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1.  Kidney International.  76:767-773. 2009
    2008 Hyperuricemia after liver transplantation in children.  Pediatric Transplantation.  12:847-853. 2008
    2007 New treatment strategies for proliferative lupus nephritis: Keep children in mind!.  Lupus.  16:684-691. 2007
    2006 Primary hyperoxaluria type 1: Still challenging!.  Pediatric Nephrology.  21:1075-1081. 2006
    2006 Hyperoxalurie primitive.  EMC - Néphrologie.  1:1-10. 2006

    Chapter

    Year Title Altmetric
    2009 Primary Hyperoxaluria.  1069-1079. 2009

    Education And Training

  • Claude Bernard University Lyon 1 Pediatrics, Residency
  • Claude Bernard University Lyon 1 Pediatrics, Postdoctoral Fellowship
  • Doctor of Philosophy, University of London - University College London 2012

    • Full Name

  • Sonia Fargue